Probiotic, lactic acid-producing bacteria and uses thereof

Details Probiotic, lactic acid-producing bacteria and uses thereof Probiotic, lactic acid-producing bacteria and uses thereof

2008-04-23

2010-10-05

Kwon, Brian-Yong S (Department: 1614)

Drug, bio-affecting and body treating compositions

Plural fermentates of different origin

C424S093450, C424S093460, C514S030000, C514S192000, C514S199000, C514S200000, C514S307000, C514S770000, C514S029000

Reexamination Certificate

active

07807151

ABSTRACT:
The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains ofBacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

REFERENCES:
patent: 4110477 (1978-08-01), Naruse et al.
patent: 4144346 (1979-03-01), Heeres et al.
patent: 4321258 (1982-03-01), Dunlap
patent: 4323651 (1982-04-01), Long et al.
patent: 4695546 (1987-09-01), Aiba et al.
patent: 4756913 (1988-07-01), Khorkova et al.
patent: 4956177 (1990-09-01), King et al.
patent: 4980180 (1990-12-01), Cully et al.
patent: 5021344 (1991-06-01), Armau et al.
patent: 5079164 (1992-01-01), Kirkovits et al.
patent: 5102800 (1992-04-01), Hirikoshi
patent: 5176911 (1993-01-01), Tosi et al.
patent: 5200336 (1993-04-01), Kong et al.
patent: 5266315 (1993-11-01), Taguchi et al.
patent: 5413960 (1995-05-01), Dobrogosz et al.
patent: 5439678 (1995-08-01), Dobrogosz et al.
patent: 5439995 (1995-08-01), Bailly et al.
patent: 5531988 (1996-07-01), Paul
patent: 5534253 (1996-07-01), Casas et al.
patent: 5665354 (1997-09-01), Neyra et al.
patent: 5785990 (1998-07-01), Langrehr
patent: 6132710 (2000-10-01), Panigrahi et al.
patent: 6461607 (2002-10-01), Farmer
patent: 6531126 (2003-03-01), Farmer
patent: 6723326 (2004-04-01), Farmer
patent: 6849256 (2005-02-01), Farmer
patent: 2003/0031659 (2003-02-01), Farmer
patent: 2006/0099197 (2006-05-01), Farmer
patent: 2008/0233104 (2008-09-01), Farmer
patent: 41 32 296 (1992-12-01), None
patent: 1 040 278 (1966-08-01), None
patent: WO 89/05849 (1989-06-01), None
patent: WO 93/14187 (1993-07-01), None
patent: WO 94/11492 (1994-05-01), None
patent: WO 96/11014 (1996-04-01), None
patent: WO 97/34615 (1997-09-01), None
patent: WO 98/54982 (1998-12-01), None
Girardin et at.(“Antimicrobial Activity of Food borne Paeibacillus and Bacillus spp. against Clostridium botulinum”, Journal of Food Protection, vol. 65, No. 5, pp. 806-813).
Rychen and Nunes (1995). B J Nutrition 74: 19-26.
Database WPI, Section Ch, Week 198918, Derwent Publications Ltd., Class B05, An 1989-136223 XP002130556 & JP 01 083025 A (Hayashi), Mar. 28, 1989, Abstract.
Database WPI, Section Ch, Week 199637, Derwent Publications Ltd., Class C05, An 1996-368043 XP002130557 & JP 08 175921 A (Idemitsu Kosan Co., Ltd.), Jul. 9, 1996, Abstract.
Fernandez, et al., 1998. Effect of diatomaceous earth as an anthelnimtic treatment on internal parasites and feedlot performance of beef steers.Animal Science66(3): 635-641.
Sussman, et al., 1986. Clinical manifestations and therapy ofLactobacillus endocarditis: report of a case and review of the literature.Rev Infect. Dis. 8: 771-776.
Hata, et al., 1988. Meningitis caused byBifidobacteriumin an infant.Pediatr. Infect. Dis. 7: 669-671.
Reid, et al, 1990. Is there a role for lactobacilli in prevention of urogenital and intestinal infections?Clin. Microbiol. Rev. 3: 335-344.
Gibson, et al., 1995. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin.Gastroenterology 106: 975-982.
Saavedra, 1994. Feeding ofBifidobacterium bifidumandStreptococcus thermophilusto infants in hospital for prevention of diarrhoea and shedding of rotavirus.Lancet 344: 1046-109.
Mitchell, 1998. Rearming in the fight against bacteria.Lancet 352: 462-463.
Shannon, 1998. Multiple-antibiotic-resistant salmonella.Lancet 352: 490-491.
Thomason, et al, 1991. Bacterial vaginosis: current review with indications for asymptomatic therapy.Am. J. Obstet Gynecol. 165: 1210-1217.
Marsh, 1993. Antimicrobial strategies in the prevention of dental caries.Caries Res. 27: 72-76.
Hill & Embil, 1986. Vaginitis: current microbiologic and clinical concepts.Can. Med. Assoc. J. 134: 321-331.
Fuller, R., 1989. Probiotics in man and animals.J. Appl. Bacteriol. 66: 365-378.
Nakamura, et al., 1988. Taxonomic study for Bacillus coagulans Hammer 1915.J. Systematic Bacterio. 38: 63-73.
Winberg, et al., 1993. Pathogenesis of urinary tract infection-experimental studies of vaginal resistance to colonization.Ped. Nephrol. 7: 509-514.
Allos, B.M., “Association betweenCampylobacterInfection and Guillain-Barré Syndrome”,J. Infect. Dis. 176: S125-S128 (1997).
Baker, H. et al, “Growth Requirements of 94 Strains of Thermophilic Bacilli”,Can. J. Microbiol. 6: 557-563 (1960).
Barefoot et al., “Antibiosis Revisited: Bacteriocins Produced by Dairy Starter Cultures”,J. Diary Sci. 76: 2366-2379 (1993).
Bernet, M.F. et al., “Adhesion of Human Bifidobacterial Strains to Cultured Human Intestinal Epithelial Cells and Inhibition of Enteropathogen-Cell Interactions”Appl. Environ. Microbiol. 59(12): 4121-4128 (1993).
Bernet, M.F. et al., “Lactobacillus acidophilusLA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria”,Gut, 35:483-489 (1994).
Black, R.E. et al, “ExperimentalCamplylobacter jejuniInfection in Humans”J. Infect. Dis. 157(3): 472-479 (1988).
Blaser, M.J. et al., “The Influence of Immunity on Raw Milk-AssociatedCampylobacterInfection”,JAMA, 257(1): 43-46 (1987).
Blaser, M.J., “Campylobacter Species” In: Principles and Practice of infectious Diseases, Eds. Mandell et al., Churchill Livingstone Inc., New York, NY 3:1649-1658 (1990).
Challa, A. et al., “Bifidobacterium longumand lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats”,Carcinogenesis, 18(3): 517-521 (1997).
Christl, et al., “Role of dietary sulphate in the regulation of methanogenesis in the human large intestine”, Gut, 33:1234-1238 (1992).
Cometta, et al., “Escherichia coliResistant to Fluoroquinolones in Patients with Cancer and Neutropenia”New Engl. J. Med., 330:1240-1241 (1994).
Database WPI, Section Ch, Week 199637, Derwent Publications Ltd., Class CO5, An 1996-368043 XP002130557 & JP 08 175921 A (Idemitsu Kosan Co., Ltd.), Jul. 9, 1996, Abstract.
De Simone, C. et al., “Effect ofBifidobacterium bifidumandLactobacillus acidophiluson gut mucosa and peripheral blood B lymphocytes”,Immunopharmacol. Immunotoxicol. 14(1&2): 331-340 (1992).
Elmer et al, “Biotherapeutic Agents: A Neglected Modality for the Treatment and Prevention of Selected Intestinal and Vaginal Infections”,JAMA, 275(11): 870-876 (1996).
Famularo, G. et al., “Stimulation of Immunity by Probiotics” In: Probiotics 2: Applications and Practical Aspects, Ed. R. Fuller, Boundary Row, London 133-161 (1997).
Gandhi, “Lactobacillus Sporogenes: An Advancement in Lactobacillus Therapy”,Townsend Lett. Doctors

Affiliated with

Also associated with

Rating

Probiotic, lactic acid-producing bacteria and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Probiotic, lactic acid-producing bacteria and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Probiotic, lactic acid-producing bacteria and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4241347